International Journal of Clinical Pharmacy

, Volume 38, Issue 5, pp 1142–1148 | Cite as

Positive correlation between etanercept concentration and the decrease in Psoriasis Area and Severity Index scale value

  • Laida ElberdínEmail author
  • Maria Outeda
  • Pilar Salvador
  • Sabela Paradela
  • Rosa María Fernández-Torres
  • Raquel Iglesias
  • Eduardo Fonseca
  • Isabel Martín
Research Article


Background In the case of psoriatic patients, only a limited number of studies have related serum biological therapies and antidrug antibodies levels to clinical response. With respect to etanercept, the available evidence has not shown any relationship yet. Objective The aim of this study was to determine if there is any correlation among etanercept serum levels, the presence of anti-etanercept antibodies and clinical response to this treatment in psoriatic patients. Setting A 1500-bed hospital (A Coruña University Hospital Complex). Method A retrospective observational study in psoriatic patients treated with etanercept (50 mg once weekly) was carried out. Psoriasis Area and Severity Index scale and adverse reactions were recorded at the time of the extraction sample. The pharmacokinetic monitoring was evaluated at the previous time points by extracting peripheral blood samples before the dose administration. Etanercept and anti-etanercept antibodies concentrations were quantified by two sandwich-type ELISA immunoassays. The patients were classified into three groups (good, partial and nonresponders) in accordance with the treatment efficacy at the blood assessment moments. The Kruskall-Wallis test and Spearman correlation assay were used to assess the efficacy and incidence of adverse effects according to the etanercept concentration and anti-etanercept antibodies, considering p values of <0.05 as statistically significant. This statistical analysis was conducted using SPSS software (version19.0). Main outcome measures Etanercept and anti-etanercept antibodies trough serum levels and clinical response. Results 38 patients were included. 26 patients (68.4 %) were good, 5 (13.2 %) were partial and 7 (18.4 %) were non-responders. There was no significant difference with respect to etanercept levels: 2.7 μg/mL (range 0.7–5.6) versus 2.2 μg/mL (range 1.0–3.5) versus 1.73 μg/mL (range 0.1–2.3), respectively (p = 0.085). Nevertheless, a positive correlation between percentage decrease in the Psoriasis Area and Severity Index scale value with respect to the baseline value and etanercept concentration was found (p = 0.011). No anti-etanercept antibodies were detected; nor was there a significant difference in the incidence of adverse effects (p = 0.8523). Conclusions Our results showed a positive correlated between etanercept concentration and the percentage decrease in the Psoriasis Area and Severity Index scale value. The incidence of anti-etanercept antibodies in psoriatic patients was low.


Anti-etanercept antibodies Etanercept Psoriasis Serum trough levels 




Conflicts of interest

Sabela Paradela, Rosa M. Fernandez-Torres and Eduardo Fonseca have participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis and in continuing medical education events supported by unrestricted educational grants from Abbvie, Celgene, Janssen-Cilag, Leo, MSD and Pfizer. The other authors have no conflicts of interest.


  1. 1.
    Aikawa NE, de Carvalho JF, Almeida Silva CA, Bonfá E. Immunogenicity of anti-TNF-α agents in autoinmune diseases. Clin Rev Allergy Immunol. 2010;38:82–9.CrossRefGoogle Scholar
  2. 2.
    Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept, a single centre, cohort study. Br J Dermatol. 2013;169:306–13.CrossRefPubMedGoogle Scholar
  3. 3.
    Cozzani E, Burlando M, Parodi A. Detection of antibodies to anti-TNF agents in psoriatic patients a preliminary study. G Ital Dermatol Venereol. 2013;148:171–4.PubMedGoogle Scholar
  4. 4.
    Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of antiTNF therapy in immune-mediated inflammatory diseases a systematic review of the literature with a metaanalysis. Ann Rheum Dis. 2013;72:1947–55.CrossRefPubMedGoogle Scholar
  5. 5.
    Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:164–72.CrossRefPubMedGoogle Scholar
  6. 6.
    Mok CC, van der Kleij D, Wolbink GJ. Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013;32:1429–35.CrossRefPubMedGoogle Scholar
  7. 7.
    Haraoui B, Cameron L, Ouellet M, White B. Antiinfliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. J Rheumatol. 2006;33:31–6.PubMedGoogle Scholar
  8. 8.
    Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis. 2015;74:e16.CrossRefPubMedGoogle Scholar
  9. 9.
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study. Ann Rheum Dis. 2010;69:817–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27:1021–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in crohn’s disease. Gastroenterology. 2009;137:1628–40.CrossRefPubMedGoogle Scholar
  15. 15.
    Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(80–4):e2.PubMedGoogle Scholar
  16. 16.
    Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol. 2004;2:542–53.CrossRefPubMedGoogle Scholar
  17. 17.
    Baert F, Noman M, Vermeire S, Van Assche G, D’ Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348:601–8.CrossRefPubMedGoogle Scholar
  18. 18.
    West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van Der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:1133–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59:49–54.CrossRefPubMedGoogle Scholar
  21. 21.
    Menting SP, van Lümig PP, de Vries AC, van den Reek JM, van der Kleij D, de Jong EM, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis: one-year follow up. JAMA Dermatol. 2014;150:130–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Matsumoto Y, Maeda T, Tsuboi R, Okubo Y. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol. 2013;40:389–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Elberdín L, Outeda M, Salvador P, Paradela S, Fernández-Torres RM, Iglesias R, et al. Infliximab drug and antibody levels in patients with dermatological conditions. Int J Clin Pharm. 2015;37:320–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Adisen E, Aral A, Aybay C, Gürer MA. Anti-infliximab antibody status and its relation to clinical response in psoriatic patients. pilot study. J Dermatol. 2010;37:708–13.CrossRefPubMedGoogle Scholar
  25. 25.
    Meyer MW, Zachariae C, Bendtzen K, Skov L. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors. Acta Derm Venereol. 2012;92:362–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol. 2013;40:39–42.CrossRefPubMedGoogle Scholar
  27. 27.
    Hsu L, Armstrong AW. Anti-drug antibodies in psoriasis a critical evaluation of clinical significance and impact on treatment response. Expert Rev Clin Immunol. 2013;9:949–58.CrossRefPubMedGoogle Scholar
  28. 28.
    Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis a systematic review. Br J Dermatol. 2014;170:261–73.CrossRefPubMedGoogle Scholar
  29. 29.
    Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48:1267–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ramírez CS, Heredia ES, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med. 2012;50:1845–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Puig L, Carrascosa JM, Daudén E, Sánchez-Carazo JL, Ferrándiz C, Sánchez-Regaña M, et al. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents. Actas Dermosifiliogr. 2009;100:386–413.CrossRefPubMedGoogle Scholar
  32. 32.
    Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012;71:88–91.CrossRefPubMedGoogle Scholar
  33. 33.
    Daïen CI, Daïen V, Parussini E, Dupuy AM, Combe B, Morel J. Etanercept concentration in patients with AR and its potencial influence on treatment decisions: a pilot study. J Rheumatol. 2012;39:1533–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Detrez I, Brouwers E, Peeters M, Geukens N, de Vlam K, Gils A. Characterization and application of a unique panel of monoclonal antibodies generated against etanercept. J Immunol. 2016;196:2879–84.CrossRefPubMedGoogle Scholar
  35. 35.
    De Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:531–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Pharmacy Department, A Coruña University Hospital ComplexIntegrated Administration ManagementA CoruñaSpain
  2. 2.Dermatology Department, A Coruña University Hospital ComplexIntegrated Administration ManagementA CoruñaSpain

Personalised recommendations